Drug Profile
Acoramidis - Eidos Therapeutics
Alternative Names: Acoramidis hydrochloride; AG-10; AG10 hydrochloride; ALXN 2060; BBP-265; Eidos Therapeutics AG10Latest Information Update: 06 Mar 2024
Price :
$50
*
At a glance
- Originator Stanford University
- Developer Alexion AstraZeneca Rare Disease; Eidos Therapeutics
- Class Benzoic acids; Ethers; Fluorobenzenes; Pyrazoles; Small molecules
- Mechanism of Action Prealbumin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Transthyretin-related hereditary amyloidosis